DA-4507 shows efficacy in models of solid and hematological malignancies

Nov. 16, 2022

At the recent Society for Immunotherapy of Cancer meeting, researchers from Dong-A ST Co. Ltd. presented preclinical data for the novel small-molecule general control nonderepressible 2 (GCN2) inhibitor, DA-4507, being developed for the treatment of cancer.

BioWorld Science Conferences New compound Cancer Immuno-oncology

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...

Today's news in brief

BioWorld

BioWorld briefs for Feb. 3, 2023.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Feb. 3, 2022.

Setpoint Medical - vagus nerve stimulation device

Setpoint Medical lands up to $145M to advance RA implant

BioWorld MedTech

Bioelectronic medicine startup Setpoint Medical Corp. raised $80 million in a preferred stock financing co-led by new investors Norwest Venture Partners and...

Brain with clock hands, day and night background

12-Hour as well as circadian brain rhythms disrupted in people with schizophrenia

BioWorld Science

Research shows that individuals with schizophrenia have abnormal gene expression patterns in their brains compared with people without the condition. In a study...

Upgrade your daily dose of biopharma and medtech news

DA-4507 shows efficacy in models of solid and hematological malignancies